Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912845 · ClinicalTrials.gov registry record · Phase 3
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
A Phase 3 study of Rabies, sponsored by Kamada.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02912845 is a Phase 3 study of Rabies that has completed, run by Kamada. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02912845, a Phase 3 study of Rabies, has completed, sponsored by Kamada.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
Conditions Studied
Interventions
- DRUG KamRAB - HRIG
Study Locations (1)
Arkansas
- ACH - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02912845
The ClinicalTrials.gov registry entry for NCT02912845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kamada, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rabies appearing as the primary indexed condition, and to 1 intervention - of which KamRAB - HRIG is the first listed.
NCT02912845 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT02912845 about?
NCT02912845 is a clinical study titled "Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies". The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to \<17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).
What is the current status of trial NCT02912845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2016-08-01. Estimated completion is 2019-11-13.
What conditions does trial NCT02912845 study?
This clinical trial studies the following conditions: Rabies.
What interventions are being tested in trial NCT02912845?
The interventions under investigation include: KamRAB - HRIG (DRUG).
Who is sponsoring clinical trial NCT02912845?
This trial is sponsored by Kamada, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02912845 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rabies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.